Switching to Mesalazine Monotherapy vs Continuing Thiopurines in Older Patients with Ulcerative Colitis in Sustained Remission: A Multicenter Randomized Controlled Trial (IDEA).
If you are an older patient with ulcerative colitis and your condition has been stable for a while, this study might be for you. Researchers want to compare two ways of managing your condition: continuing with your current medicine (called thiopurines) or switching to a different type of medicine (called mesalazine). The main goal is to see which treatment strategy is better at preventing your symptoms from returning. They will also look at how long you stay well, if you need hospital treatment, and any side effects. This research aims to understand the best long-term care for older people with ulcerative colitis.
At a glance
What is this study about?
This study is about helping older patients with a bowel condition called ulcerative colitis. If you have this condition, your large bowel (colon) becomes inflamed and develops small sores. This can cause tummy pain, diarrhoea, and blood in your poo. Many people take medicines to help keep these symptoms under control, and some are lucky enough to have long periods where they feel completely well, known as 'remission'.
For older patients who have been feeling well for a while, doctors sometimes want to know the best way to keep them well in the long term. Currently, some patients take a type of medicine called thiopurines, which can be very effective. This study wants to see if switching to a different medicine called mesalazine, which is often considered gentler, is just as good, or even better, at preventing symptoms from coming back. It's a bit like asking if a different maintenance plan for a car works just as well as the usual one.
The main thing the study will check is whether your ulcerative colitis stays quiet. They will do this by looking at specific markers in your stool (poo) that show inflammation, or if your symptoms get worse and you need more intense treatment. They will also keep an eye on other important things like how long you stay well, whether you need to go to hospital, and if you experience any side effects from the medicines. The overall aim is to find effective and safe ways to manage ulcerative colitis for older patients over many years.
Key takeaways
- Compares two treatments for stable ulcerative colitis.
- Aimed at older patients (18+ years) in remission.
- Checks which medication best prevents symptoms from returning.
- Monitors for 2 years, looking at health and side effects.
- Could help improve future care for ulcerative colitis patients.
Who may be eligible?
This study is looking for both men and women. To take part, you need to be an adult, aged 18 or older. There is no upper age limit, meaning older adults are very welcome to join.
A key requirement is that you have a diagnosis of ulcerative colitis. Crucially, your condition must be in 'sustained remission'. This means your symptoms have been under control and you've been feeling well for a consistent period, suggesting your current treatment is working.
Your doctor will check other specific health details to make sure this study is right for you and that taking part would be safe. They will go through all the criteria with you in detail.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of ulcerative colitis?
- Has your ulcerative colitis been stable and in remission for a while?
- Are you currently taking thiopurine medication for your ulcerative colitis?
- Are you comfortable with attending regular check-ups for two years?
What does participation involve?
If you decide to take part, you would be randomly put into one of two groups. One group would continue with their current thiopurine medication, and the other group would switch to mesalazine medicine. The specific mesalazine drug and dose would be chosen by your doctor from a list of approved options, such as Salofalk, Pentasa, Asacol, or Claversal, tailored to your needs. This is a long-term study, as researchers want to see how the treatments work over 24 months (two years).
You would have regular check-ups and assessments during this time. These visits would involve monitoring your symptoms, possibly providing stool samples to check for inflammation, and discussing any side effects you might be experiencing. The medical team would keep a close eye on your health and well-being throughout the study period.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is ulcerative colitis?
It's a long-term condition where your large bowel (colon) and rectum become inflamed, causing tummy pain, diarrhoea, and sometimes blood in your poo.
What does 'sustained remission' mean?
It means your ulcerative colitis symptoms have been under control and you've been feeling well for a while.
What are thiopurines and mesalazine?
They are different types of medicines used to treat ulcerative colitis and reduce inflammation in the bowel.
How long will the study last?
The study will last for 24 months, which is two years.
Will I have to pay for anything?
No, all study-related visits and medications will be provided as part of the research.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.